Arcturus's Differentiated RNA Technology Faces First Clinical Test In 2017
Executive Summary
Emerging Company Profile: San Diego-based Arcturus Therapeutics has developed technology for the targeted delivery of RNA therapeutics, which Johnson & Johnson's Janssen subsidiary will evaluate for the first time in humans in a clinical trial starting as early as this year for the partners' hepatitis B drug candidate.
You may also be interested in...
Finance Watch: Landos Raises $60m Series B Round Ahead Of Phase II Data In 2020
If Landos goes public late next year, its financing strategy will align with venture capital and IPO trends observed in a new Jefferies report. Also, D&D Pharmatech raises $137.1m in VC cash, Sonnet secures up to $100m and the CF Foundation commits up to $15m to Arcturus.
Arcturus Enters Reverse-Merger With Alcobra To Push Differentiated RNA Approach
One company’s disappointment is another’s opportunity, as Arcturus will go public by merging with troubled Alcobra. The combined company will have seven preclinical programs, four run by partners.
Deals Shaping The Medical Industry, July 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.